ChemoCentryx is a biopharmaceutical company focused exclusively on discovering, developing and commercializing orally-administered therapeutics to treat autoimmune diseases, inflammatory disorders and cancer. Our drug candidates target specific chemokines or chemo-attractant receptors, thereby blocking the inflammatory response driven by that particular chemokine while leaving the rest of the immune system unaffected. Our goal is to discover, develop and commercialize therapeutics with distinct advantages over currently marketed therapies in our disease areas of focus, thereby maximizing shareholder value.
4:00 PM ET on Jul 7, 2015
Delayed at least 20 minutes.
Provided by eSignal.
May 29, 2015
Positive Results From ChemoCentryx Phase II Diabetic Nephropathy Trial With Chemokine Receptor CCR2 Inhibitor CCX140 Highlighted at the 52nd ERA-EDTA Congress
May 26, 2015
Positive Clinical Data From ChemoCentryx Phase II Trial in Diabetic Nephropathy to be Presented at the 52nd Annual ERA-EDTA Congress
May 12, 2015
ChemoCentryx to Present at Two Upcoming Investor Conferences
^ Return to Top